XYLYX BIO Launches Specialized Contract R&D Services That Support Improved Assessment of Antifibrotic Drug Candidate Efficacy

Xylyx Bio | September 30, 2020

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to humans. Commonly used assays have limited ability to predict how a drug candidate will act when introduced into patients, costing biopharma companies billions in the quest to determine which drugs will be most effective. To address this, Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio's custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.


Research biospecimens are commonly stored at -80ºC, but this usually occurs inside mechanical reach-in freezers that result in minor, transient exposure of workers to the extreme cold. Why construct a walk-in 80ºC freezer? The design and construction of a walk-in freezer offers high density storage and savings in energy, maintenance, and replacement costs compared to -80ºC mechanical freezers. Companies can expect an return on operational savings of 2 to 3 years.

Other News

Medolife Rx Announces Changes to Management and Improvements to AELIA’s Marketing Efforts

Medolife Rx, Inc. | February 07, 2022

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online presence. The Company’s manager of marketing and brand development, Maggie Dumais, has stepped down from their position under mutual agreement with the Company. In order to support the Company’s vision of a new marketing strategy, Medolife is finalizing an agreement with a new director of marketing and brand development, whose name will be announced at a later date. “We are excited with the new direction that the Company is taking with its AELIA products and expect a positive outcomeThe Company’s values, goals and plans will be presented in a way that reflects our mission to promote health and well-being with our expanding line of products.” Medolife CEO Dr The Company also hired a new team to oversee the overhaul of AELIA’s websites, product listings and social media presence. The Company hopes that, with the help of these experienced professionals, their online platforms will see an increase in sale conversions and consumer feedback. Medolife thanks its shareholders and clients for believing in them. The Company will have more positive news coming out soon. About Medolife Rx Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian, who pioneered the unlaying polarization technology, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company intends to pursue product registration and drug approval in multiple countries. Through its subsidiary AELIA, Medolife manufactures and distributes consumer wellness products in consumer areas such as pain relief, beauty, and general wellness. AELIA products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption. Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife could have the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.

Read More


Taysha Gene Therapies Added to the Nasdaq Biotechnology Index

Taysha Gene Therapies | December 16, 2021

Taysha Gene Therapies Inc. a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced that it has been added to the Nasdaq Biotechnology Index in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021. “We are pleased to announce Taysha’s inclusion in the Nasdaq Biotechnology Index. As we continue to advance our broad pipeline and execute on our near-term clinical and regulatory milestones, inclusion in this index will enhance our visibility and expand awareness of our story with investors.” RA Session II, President, Founder and CEO of Taysha The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December. About Taysha Gene Therapies Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.

Read More


Botanical Solution Inc. (BSI) Secures $6.1 Million in Series A First Closing

Botanical Solution Inc. | January 18, 2022

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. For agricultural markets, this Series A round of funding will support the production and sales growth of BSI’s first commercially successful product marketed as BotriStop® and its recently announced global brand Quillibrium®, which are based on a tissue cultured tree native to Chile, the Quillaja saponaria. The product has been used successfully on a wide variety of fruits and vegetables throughout Chile. Quillibrium® was launched in Peru last year with great success and will soon reach growers across Mexico through BSI’s main distribution partner Syngenta. Quillibrium® continues regulatory progress in the US and will soon initiate registration in additional countries to expand its global footprint. This new funding will also accelerate market readiness of new botanical biopesticide products currently in later development stages and enable the expansion of BSI’s R&D pipeline. For pharmaceutical markets, BSI’s new funding will vastly increase the quantity of Quillaja saponaria plants that can be grown at BSI’s labs and the sustainable production of billions of doses of gold standard adjuvant QS-21, traditionally obtained from old native trees that are increasingly affected by climate change and strict deforestation laws in Chile. QS-21 is currently used in Covid-19 and malaria vaccines, as well as a blockbuster shingles vaccine. With this funding BSI will become a major supplier of pharmaceutical grade QS-21. BSI CEO Gastón Salinas declared, “The BSI team is really excited to welcome Otter Capital. We are happy to reconfirm the strong commitment from our current investors, as well. BSI is building strong foundations to deliver the world’s most advanced botanical biopesticides and ensure the supply of the gold standard vaccine adjuvant QS-21.” According to John Pasquesi, Managing Member at Otter Capital, “I am excited to partner with BSI. BSI has established a strong market presence via distribution agreements with Syngenta and effective, profitable products. BSI’s product development platform is efficient and scalable. Botanical products have excellent consistency and BSI’s approach is truly sustainable. These products have applications in two very large markets – agriculture and pharmaceuticals. I am very impressed by the team at BSI and the progress they have made with limited resources under Gastón’s leadership.” Two longtime investors joining Otter Capital in this First Closing of the Series A are Inversiones el Coigue and Inversiones Eurocel, both based in Santiago, Chile. About BSI BSI, a Delaware Corporation has a proprietary R&D platform for truly sustainable and improved production of consistent and high- quality Advanced Botanical Materials (ABM). ABM-01 is the first ABM produced by the company, based on a tissue cultured plant called Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, BSI’s biopesticide Quillibrium® and the adjuvant QS-21, used in modern vaccine development. About Otter Capital Otter Capital was founded by John Pasquesi to make a variety of private equity investments. Otter Capital has a strong track record investing in leading edge agriculture companies. Otter was an early and consistent investor in AgraQuest, a leading biopesticide company where Mr. Pasquesi served as chairman of the board of directors. In 2012, Bayer CropScience acquired AgraQuest for $425 million. More recently, Otter Capital invested in the agricultural biotechnology companies BioConsortia, Inc. and NewLeaf Symbiotics, Inc. Mr. Pasquesi serves on the board of directors of BioConsortia and as chairman of the board of NewLeaf. Otter Capital is an investor in Inguran LLC dba Sexing Technologies, the world’s leading supplier of sexed semen to the dairy industry and a leading provider of dairy and beef genetics. Mr. Pasquesi serves on the board of managers of Inguran.

Read More


Nexeo Plastics and Earth Renewable Technologies Sign Agreement to Distribute BioCompounds in North America

Nexeo Plastics | March 02, 2022

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our renewable solutions line card.” Arturo Hoyo, Nexeo Plastics’ Vice President of Product Line Management Compostable, biobased and/or biodegradable, ERT’s plant-based BioCompounds perform like conventional plastics and are often ideal for a wide range of uses, including single-use and one-time niche applications, such as bags, bottles and cutlery. “We want to make the world more sustainable by improving the availability of sustainable materials that can perform like plastic,” said ERT President Kim Fabri. “Nexeo Plastics’ reach in North America, their understanding of the value of sustainable material, and their growing portfolio of sustainable products makes them an ideal partner for us.” About Nexeo Plastics Nexeo Plastics is a leading global thermoplastic resins distributor, representing quality products from world-class suppliers, and serving a diverse customer base across North America, Latin America, Europe, Middle East, Africa and Asia. From material selection assistance to identifying supply chain and inventory solutions, we go beyond traditional logistics to provide value-added services across many industries, including automotive, healthcare, packaging, wire and cable, 3D printing and more. About Earth Renewable Technologies Earth Renewable Technologies, Inc. (ERT) was founded in 2009 with the mission of replacing plastic packaging with biodegradable materials. ERT patented SFRP (Short Fiber Reinforced Polymer), a pioneering technology capable of drastically modifying the performance of biopolymers and delivering previously unknown applications for these materials. Since then, the company has been introducing new technologies to the market, revolutionizing the biopolymer market and allowing companies to truly move towards a circular economy.

Read More


Research biospecimens are commonly stored at -80ºC, but this usually occurs inside mechanical reach-in freezers that result in minor, transient exposure of workers to the extreme cold. Why construct a walk-in 80ºC freezer? The design and construction of a walk-in freezer offers high density storage and savings in energy, maintenance, and replacement costs compared to -80ºC mechanical freezers. Companies can expect an return on operational savings of 2 to 3 years.